Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
191 results about "Osteopontin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Osteopontin (OPN), also known as bone sialoprotein I (BSP-1 or BNSP), early T-lymphocyte activation (ETA-1), secreted phosphoprotein 1 (SPP1), 2ar and Rickettsia resistance (Ric), is a protein that in humans is encoded by the SPP1 gene (secreted phosphoprotein 1). The murine ortholog is Spp1. Osteopontin is a SIBLING (glycoprotein) that was first identified in 1986 in osteoblasts.
Multifactorial assay for cancer detection
InactiveUS20050069963A1Rapid and early detectionPeptide/protein ingredientsMicrobiological testing/measurementAnti her2Anti-MUC-1
Provided are methods for the rapid detection of ovarian cancer. The methods employ a multiplex immunoassay to detect levels of two or more of the markers EGF, G-CSF, IL-6, IL-8, CA-125, VEGF, MCP-1, anti-IL6, anti-IL8, anti CA-125, anti-c-myc, anti-p53, anti-CEA, anti-CA 15-3, anti-MUC-1, anti-survivin, anti-bHCG, anti-osteopontin, anti-PDGF, anti-Her2 / neu, anti-Akt1, anti-cytokeratin 19, cytokeratin 19, EGFR, CEA, kallikrein-8, M-CSF, FasL, ErbB2 and Her2 / neu in a sample of the patient's blood, where the presence of abnormal levels of two or more of the markers indicates the presence of ovarian cancer in the patient. An array also is provided to quantitate levels of these markers in a patient's blood. Also provided is a method of predicting onset of clinical ovarian cancer comprising determining the change in concentration over time of two or more of anti-Her2 / neu, anti-MUC-1, anti-c-myc, anti-p53, anti-CA-125, anti-CEA, anti-CA 72-4, anti-PDGFRα, IFNγ, IL-6, IL-10, TNFα, MIP-1α, MIP-1β, EGFR and Her2 / neu in a patient's blood.
Owner:UNIVERSITY OF PITTSBURGH
Recombinant anti-osteopontin antibody and use thereof
A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.
Owner:JURIDICAL FOUND THE CHEMO SERO THERAPEUTIC RES INST +1
Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
InactiveUS20060078941A1Highligthing the divergence of gene expressionMicrobiological testing/measurementBiological testingKallikrein-10Gene family
Gene expression profiling and hierarchial clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1 / Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2 / differentially expressed in ovarian carcinoma 2 (Dab2 / DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1 / Ep-CAM by monoclonal chimeric / humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas. Claudin-3 and claudin-4 being receptors for Clostridium Perfringens enterotoxin, this toxin may be used as a novel therapeutic agent to treat ovarian serous papillary tumors.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS
Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said method
InactiveUS20110045511A1Useful predictionOrganic active ingredientsBiological material analysisFibroblast growth factor receptor 2Biomarker (petroleum)
The present invention relates generally to methods of in vitro diagnostics, in particular the use of a compound selected from the group consisting of fibroblast growth factor 23 (FGF23), inorganic phosphorus (P), the product of inorganic phosphorus and total calcium (P×tCa), osteopontin (OPN) and parathyroid hormone (PTH) as biomarker. Said biomarkers can be used to monitor the modulation of fibroblast growth factor receptor (FGFR) kinase activity, in particular its inhibition, and / or the occurrence of secondary effects of FGFR inhibition. The invention further provides methods and kits relating to these uses.
Owner:NOVARTIS AG
Osteopontin as Novel Prognostic Biomarker for Heart Failure
InactiveUS20100267062A1Improve non invasive monitoringReduce functionMicrobiological testing/measurementDisease diagnosisPlasma samplesOsteopontin Gene
The present invention relates to methods for providing a diagnosis, prognosis and / or risk stratification of a subject with heart failure, comprising determining the concentration of osteopontin (OPN) in the biological sample, preferably in a plasma sample. An OPN cut-off value is discloses as a valuable reference value. The present invention furthermore relates to the use of osteopontin as marker for diagnosis, prognosis and / or risk stratification of a subject with heart failure, the use of the determination of the osteopontin plasma concentration in a biological sample of a subject for diagnosis, prognosis and / or risk stratification of heart failure as well as kits for performing the methods and uses of the invention. The present invention allows particularly for risk stratification of patients with heart failure, such as mortality prediction and prognosis of heart failure severity.
Owner:UNIVERSITATSKLINIKUM HEIDELBERG
Dairy cattle breeding for improved milk production traits in cattle
InactiveUS20070015164A1Highly desirable milk production traitIncreased milk fatSugar derivativesMicrobiological testing/measurementHeifer calfMilk cow's
Nucleic acid molecules comprising a SNP site selected from the group consisting of position 1296 of bovine uterine milk protein (UTMP) coding sequence (SEQ ID NO: 1), position 213 of bovine signal transducer and activator of transcription (STAT1) coding sequence (SEQ ID NO: 2), position 8514 of the osteopontin (OPN) gene (SEQ ID NO: 3), or position 1070 of a bovine lectin-like oxidized LDL receptor (OLR1) coding sequence (SEQ ID NO: 4), which SNP indicates a desirable milk production trait in a dairy cattle. Also disclosed are an array or a kit comprising the same, a method for detecting the SNPs, a method for progeny testing of cattle, and a method for selectively breeding of cattle.
Owner:WISCONSIN ALUMNI RES FOUND
Methods of detecting ovarian cancer based on osteopontin
InactiveUS20050009120A1Improve reliabilitySugar derivativesMicrobiological testing/measurementGynecologyOsteopontin Gene
The present invention is directed to diagnostic methods based upon the expression of the protein osteopontin. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Osteopontin-coated surfaces and methods of use
InactiveUS20060105013A1Increase ratingsEasy to placeDental implantsPeptide/protein ingredientsOsseointegrationMotility
An osteopontin containing implant which increases the rate of osseointegration and the percentage of bone apposition is described. In one embodiment, the implant includes osteopontin or an active fragment thereof or an active peptide derived thereform. In another embodiment, the implant includes a material suitable for use in vivo within a subject in combination with a releasable form of osteopontin forming an osteopontin containing implant. The disclosed osteopontin derived peptides bind to various cell types and play important roles in cellular differentiation and / or motility. Many of these interactions are mediated by integrins as disclosed. Antibodies provide a mechanism to abolish or attenuate the activities of the claimed peptides.
Owner:CHILDRENS MEDICAL CENT CORP
Use of protein biomolecular targets in the treatment and visualization of brain tumors
Owner:ER SQUIBB & SONS INC
Recombinant anti-osteopontin antibody and use thereof
Owner:JURIDICAL FOUND THE CHEMO SERO THERAPEUTIC RES INST +1
Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
InactiveUS20050048535A1Highligthing the divergence of gene expressionBioreactor/fermenter combinationsNanotechAbnormal tissue growthKinin
Gene expression profiling and hierarchial clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1 / Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2 / differentially expressed in ovarian carcinoma 2 (Dab2 / DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1 / Ep-CAM by monoclonal chimeric / humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas.
Owner:BIOVENTURES LLC
Osteopontin for the Prediction and Treatment of Cardiovascular Diseases
InactiveUS20100150877A1Augment osteopontin gene expressionFunction increaseOrganic active ingredientsPeptide/protein ingredientsOsteopontinVascular disease
Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.
Owner:THE NAT UNIV OF IRELAND GALWAY
Osteopontin-related compositions and methods
InactiveUS20050119204A1Reduce the amount requiredAvoid seizuresAntibacterial agentsNervous disorderDiseaseOsteopontin Gene
This invention provides a method for reducing the amount of osteopontin in an osteopontin-expressing cell comprising introducing into the cell a nucleic acid which specifically inhibits osteopontin expression in the cell. This invention also provides methods for inhibiting the onset of, and treating, osteopontin-related disorders, as well as compositions for practicing the same. This invention further provides methods for determining the amount of osteopontin in a sample, and a kit for practicing the same. This invention also provides methods for determining whether an agent reduces the amount of osteopontin in an osteopontin-expressing cell. Finally, this invention provides methods for treating a subject afflicted with a disorder mediated by an endogenous protein.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
ActiveUS20160272973A1Reduce inflammationRelieve symptomsSpecial deliveryGenetic material ingredientsProgenitorHeart cells
Various therapeutic polynucleotides are provided along with their use to treat a variety of disease states. The chimeric polynucleotides disclosed herein comprise an OPN aptamer linked to an OPN-specific therapeutic oligonucleotide in order to deliver the OPN-specific therapeutic polynucleotide to the site of OPN expression. Thus, the specificity of OPN aptamers allows delivery of therapeutic molecules to the site of unhealthy tissue. Accordingly, the chimeric polynucleotides disclosed herein can reduce at least one symptom of a disease or unhealthy condition by delivering an OPN-specific therapeutic oligonucleotide that interferes with a disease promoting factor.
Owner:SHEHADEH LINA A
Osteopontin Specific Antibodies and Methods of Use Thereof
InactiveUS20100129376A1Nervous disorderImmunoglobulins against animals/humansOsteopontin GeneOsteopontin
Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders.
Owner:DENHARDT DAVID T +1
Infant milk powder rich in osteopontin
PendingCN104489101AEnhance physical fitnessPromote growthMilk preparationOsteopontin GeneOsteopontin
The invention relates to the technical field of formula milk powder, and in particular relates to infant formula milk powder. The formula milk powder is rich in 0.02wt%-0.24wt% of osteopontin.
Owner:AUSNUTRIA DAIRY CHINA
Fibroblast growth factor receptors and methods for their use
InactiveUS20070110752A1Reduce expressionPeptide/protein ingredientsGenetic material ingredientsAutoimmune conditionHepatocellular carcinoma
Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide finction. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.
Owner:GENESIS RES & DEV
Bovine osteopontin formulations for the improvement of the wound healing process
InactiveUS20070232526A1Organic active ingredientsPeptide/protein ingredientsMedicineOsteopontin Gene
Topical formulations containing bovine osteopontin for improved wound healing. The wound can be infected or inflamed or it can be a diabetic wound.
Owner:KVISTGAARD ANNE STAUDT +2
Fibroblast growth factor receptors and methods for their use
InactiveUS20060115483A1Reduced gene expressionDecreasing osteopontin gene expressionAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAutoimmune conditionHepatocellular carcinoma
Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.
Owner:GENESIS RES & DEV
Fibroblast growth factor receptors and methods for their use
InactiveUS20050112642A1Reduced gene expressionDecreasing osteopontin gene expressionPeptide/protein ingredientsAntibody mimetics/scaffoldsAutoimmune conditionHepatocellular carcinoma
Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5. Such binding agents and modulators of FGFR5 gene expression may be employed for the treatment of disorders including: osteopontin-mediated diseases; autoimmune diseases, such as systemic lupus erythematosus; bone disorders such as osteoporosis and osteopetrosis; and cancers, including cellular carcinomas such as hepatocellular carcinomas.
Owner:GENESIS BIOSCIENCES LTD +1
Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
InactiveUS7083791B2Reduce decreaseDecreasing osteopontin gene expressionOrganic active ingredientsBiocideHepatocellular carcinomaAutoimmune disease
Isolated fibroblast growth factor receptor (FGFR5) polypeptides and polynucleotides encoding such polypeptides are provided. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to and agonize or antagonize FGFR5 polypeptide function. Specific binding molecules include antibodies, functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5 and, thus, are effective agents suitable for the treatment of diseases such as osteopontin-mediated autoimmune disease, such as systemic lupus erythematosus, bone disorders including osteoporosis and osteopetrosis, and cancers, including cellular carcinomas such as hepatocellular carcinomas.
Owner:GENESIS RES & DEV
Osteopontin Specific Antibodies and Methods of Use Thereof
InactiveUS20090047289A1Useful in treatingInhibit and promote osteoporosisNervous disorderImmunoglobulins against animals/humansDiseaseOsteopontin Gene
Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders.
Owner:DENHARDT DAVID T +1
Urine and Serum Biomarkers Associated with Diabetic Nephropathy
Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.
Owner:BIO PREVENTIVE MEDICINE CORP
Assessing colorectal cancer by measuring osteopontin and carcinoembryonic antigen
InactiveUS20090075312A1Microbiological testing/measurementBiological material analysisCarcinoembryonic antigenOsteopontin Gene
The present invention relates to a method aiding in the assessment of colorectal cancer (=CRC). It discloses the use of a marker combination comprising osteopontin and carcinoembryonic antigen in the assessment of colorectal cancer. Furthermore, it especially relates to a method for assessing colorectal cancer from a liquid sample, derived from an individual by measuring at least the markers osteopontin and carcinoembryonic antigen in said sample. The marker combination comprising osteopontin and carcinoembryonic antigen can, e.g., be used in the early detection of colorectal cancer or in the surveillance of patients who undergo therapy, e.g., surgery.
Owner:ROCHE DIAGNOSTICS OPERATIONS +1
Infant formula
InactiveUS20050287247A1Facilitate acquisitionReduce impaired immune functionMilk preparationPeptide/protein ingredientsBaby foodOsteopontin
Infant formula containing osteopontin and use of osteopontin as supplement for infant formulas or baby food.
Owner:ARLA FOODS AMBA
Anti-osteopontin OPN monoclonal antibody and application thereof
InactiveCN101891814AImmunoglobulins against animals/humansPeptide preparation methodsDiseaseOsteopontin Gene
The invention relates to an anti-osteopontin OPN monoclonal antibody, an application thereof in preparing a medicament for treating diseases mediated by OPN, an application thereof in preparing a kit for detecting the OPN, a hybridoma cell strain generating the monoclonal antibody, and the kit containing the monoclonal antibody.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
Use of osteopontin for the treatment and/or prevention of neurologic diseases
InactiveUS7217687B2Promoting myelination and regeneration of nerveGood effectOrganic active ingredientsNervous disorderNervous systemOsteopontin Gene
The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.
Owner:MERCK SERONO SA
Assessment method for prostatic cancer onset risk gene and diagnostic kit
The invention discloses an assessment method for early assessing the onset risk of prostatic cancer by using polymorphism of an osteopontin gene and a diagnostic kit. The invention belongs to biotechnology invention and is mainly characterized in that genetic typing is carried out on a haplotype comprising SNP (Single Nucleotide Polymorphism) (10), SNP (11), SNP (13), SNP (15), SNP (22) rs2853749 and SNP (23) rs2853750 and haplotype comprising SNP (35) rs6532039, SNP (49) rs4754 and SNP (59) rs1126616 in osteopontin (OPN) gene, so that the onset risk of the prostatic cancer can be assessed and early diagnosis and differential diagnosis are realized. The assessment method and the diagnostic kit disclosed by the invention are suitable for onset risk evaluation and early diagnosis of physical examination people and individuals with cancer family history and examination will or can be used for differential diagnosis of the prostatic cancer and benign prostatic hyperplasia.
Owner:SHENYANG MEDICAL COLLEGE
Method for producing anti-osteopontic antibody medicine and use
InactiveCN1351888AInhibit migrationPrevent proliferationAntibody ingredientsFermentationRestenosisSingle-Chain Antibodies
The present invention relates to the field of biological preparation technology. By means of bioengineering process, the humanized anti-osteopontin single chain antibody, anti-osteopontin monoclonal antibody and anti-osteopontin polyclonal antibody are produced and made into various medicament forms and are used in preventing and treating vascular re-stenosis, atheoscleorsis and osteoporosis. The present invention has the features of novel materials, unique and reasonable production process, high curative effect and no toxic side-effect, and wide application prospect.
Owner:HEBEI MEDICAL UNIVERSITY
Method for extracting osteopontin in cow's milk
InactiveCN101485381ASimple and fast operationLow costAnimal proteins working-upChromatographic separationFreeze-drying
The invention discloses a method for extracting osteopontin in cow milk, relates to a method for extracting osteopontin, and solves the problem that the extracted osteopontin in the cow milk has low purity in the prior art. The extracting method comprises the following steps of ion-exchange chromatographic separation, primary hydrophobic chromatographic separation, secondary hydrophobic chromatographic separation, dialysis, and freeze-drying to prepare the osteopontin in the cow milk. The extracted osteopontin in the cow milk has high purity. The method does not adopt a step of protein denaturation, and has the advantages of simple and convenient operation, low cost, and short extraction time.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com